Form 4: Corcept Therapeutics Executive William Guyer Reports Stock Transaction
SEC Form 4 Filing
William Guyer, Chief Development Officer of Corcept Therapeutics, reports the disposal of 604 shares to cover tax obligations related to vesting restricted stock units.
Summary
- On March 1, 2024, William Guyer, Chief Development Officer of Corcept Therapeutics, disposed of 604 shares of common stock to satisfy tax withholding obligations.
- The shares were sold at a price of $24.06 per share.
- Following the transaction, Guyer directly owns 6,039 shares of Corcept Therapeutics, which includes unvested restricted stock awards and units.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment about the company's performance or prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor potential insider trading activity and assess management's confidence in the company's prospects.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of stock disposal for tax obligations. |
| 03/05/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.